Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Accelerating therapeutic discoveries for heart failure: a new public–private partnership

The Accelerating Medicines Partnership in Heart Failure is designed to deliver tools and knowledge that enable the development of new approaches to treat heart failure with preserved ejection fraction, which is considered the largest unmet need in cardiovascular medicine.
  1. Sanjiv J. Shah

    1. Northwestern University, Chicago, IL, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Javed Butler

    1. Baylor Scott White Research Institute, Dallas, TX, USA; University of Mississippi Medical Center, Jackson, MS, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Svati H. Shah

    1. Duke University, Durham, NC, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Tania N. Kamphaus

    1. Duke University, Durham, NC, USA.*These authors contributed equally to this work.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Vandana Sachdev

    1. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. *These authors contributed equally to this work.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for ~50% of all HF cases globally1, and the incidence and prevalence of HFpEF are increasing. Patients with HFpEF face a high risk for mortality, recurrent hospitalizations, and reduced quality of life and functional capacity. To date, no therapies have convincingly reduced mortality in patients with HFpEF, and few trials have shown a reduction in risk of hospitalization2.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 781-782 (2022)

doi: https://doi.org/10.1038/d41573-022-00158-3

Acknowledgements

The authors would like to thank those colleagues who dedicated 9 months to the Design Phase to shape the AMP HF, with adept facilitation by L. Nguyen of FNIH. Members comprise leadership at the NHLBI, FDA and industry (Abbott, Amgen, Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals & Eli Lilly Alliance, Bristol Myers Squibb, Cytokinetics, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Novartis AG and Novo Nordisk), as well as academic advisors. D. Goff from NHLBI provided valuable leadership support throughout the Design Phase. The authors would further like to recognize, in memoriam, Robb Kociol, who served in the leadership role and whose insights in helping to shape this programme will be an indelible part of his legacy. The Design Phase work was made possible with funding from the industry partners and from the FNIH Charles A. Sanders Legacy Fund.

Disclaimer

The content of this manuscript is solely the responsibility of the authors and does not necessarily reflect the official views of the NHLBI, NIH or the United States Department of Health and Human Services.

References

  1. Shah, S. J. et al. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute working group summary. Circulation 141, 1001–1026 (2020).

    Article  PubMed  Google Scholar 

  2. Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2206286 (2022).

  3. Dolgin, E. Massive NIH–industry project opens portals to target validation. Nat. Rev. Drug Discov. 18, 240–242 (2019).

    Article  Google Scholar 

  4. Menetski, J. P. et al. The Foundation for the National Institutes of Health Biomarkers Consortium: past accomplishments and new strategic direction. Clin. Pharmacol. Ther. 105, 829–843 (2019).

    Article  PubMed  Google Scholar 

  5. Shah, S. J. et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131, 269–279 (2015).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary figure

Competing Interests

S.J.S. has received research grants from the National Institutes of Health (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squib, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. J.B. has received consulting fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, and Vifor. S.H.S. has received research funding through sponsored research agreements between AstraZeneca and Verily, and Duke University. The other authors have no relevant disclosures.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links